Indianapolis, IN 46202, USA.
Am J Physiol Gastrointest Liver Physiol. 2011 Oct;301(4):G739-47. doi: 10.1152/ajpgi.00432.2010. Epub 2011 Jun 23.
AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-α (PPAR-α) are critical regulators of short-term and long-term fatty acid oxidation, respectively. We examined whether the activities of these molecules were coordinately regulated. H4IIEC3 cells were transfected with PPAR-α and PPAR-γ expression plasmids and a peroxisome-proliferator-response element (PPRE) luciferase reporter plasmid. The cells were treated with PPAR agonists (WY-14,643 and rosiglitazone), AMPK activators 5-aminoimidazole-4-carboxamide riboside (AICAR) and metformin, and the AMPK inhibitor compound C. Both AICAR and metformin decreased basal and WY-14,643-stimulated PPAR-α activity; compound C increased agonist-stimulated reporter activity and partially reversed the effect of the AMPK activators. Similar effects on PPAR-γ were seen, with both AICAR and metformin inhibiting PPRE reporter activity. Compound C increased basal PPAR-γ activity and rosiglitazone-stimulated activity. In contrast, retinoic acid receptor-α (RAR-α), another nuclear receptor that dimerizes with retinoid X receptor (RXR), was largely unaffected by the AMPK activators. Compound C modestly increased AM580 (an RAR agonist)-stimulated activity. The AMPK activators did not affect PPAR-α binding to DNA, and there was no consistent correlation between effects of the AMPK activators and inhibitor on PPAR and the nuclear localization of AMPK-α subunits. Expression of either a constitutively active or dominant negative AMPK-α inhibited basal and WY-14,643-stimulated PPAR-α activity and basal and rosiglitazone-stimulated PPAR-γ activity. We concluded that the AMPK activators AICAR and metformin inhibited transcriptional activities of PPAR-α and PPAR-γ, whereas inhibition of AMPK with compound C activated both PPARs. The effects of AMPK do not appear to be mediated through effects on RXR or on PPAR/RXR binding to DNA. These effects are independent of kinase activity and instead appear to rely on the activated conformation of AMPK. AMPK inhibition of PPAR-α and -γ may allow for short-term processes to increase energy generation before the cells devote resources to increasing their capacity for fatty acid oxidation.
AMP 激活的蛋白激酶 (AMPK) 和过氧化物酶体增殖物激活受体-α (PPAR-α) 分别是短期和长期脂肪酸氧化的关键调节因子。我们研究了这些分子的活性是否协调调节。将 PPAR-α 和 PPAR-γ 表达质粒和过氧化物酶体增殖物反应元件 (PPRE) 荧光素酶报告质粒转染到 H4IIEC3 细胞中。用 PPAR 激动剂 (WY-14,643 和罗格列酮)、AMPK 激活剂 5-氨基咪唑-4-甲酰胺核苷 (AICAR) 和二甲双胍以及 AMPK 抑制剂化合物 C 处理细胞。AICAR 和二甲双胍均降低了基础和 WY-14,643 刺激的 PPAR-α 活性;化合物 C 增加激动剂刺激的报告基因活性,并部分逆转 AMPK 激活剂的作用。对 PPAR-γ 也有类似的影响,AICAR 和二甲双胍均抑制 PPRE 报告基因活性。化合物 C 增加了基础 PPAR-γ 活性和罗格列酮刺激的活性。相比之下,视黄酸受体-α (RAR-α),另一种与视黄酸 X 受体 (RXR) 二聚化的核受体,受 AMPK 激活剂的影响不大。化合物 C 适度增加 AM580(一种 RAR 激动剂)刺激的活性。AMPK 激活剂不影响 PPAR-α 与 DNA 的结合,并且 AMPK 激活剂和抑制剂对 PPAR 和 AMPK-α 亚基核定位的影响之间没有一致的相关性。表达组成型激活或显性负性 AMPK-α 抑制基础和 WY-14,643 刺激的 PPAR-α 活性以及基础和罗格列酮刺激的 PPAR-γ 活性。我们得出结论,AMPK 激活剂 AICAR 和二甲双胍抑制 PPAR-α 和 PPAR-γ 的转录活性,而用化合物 C 抑制 AMPK 则激活这两种 PPAR。AMPK 的作用似乎不是通过对 RXR 或 AMPK/RXR 与 DNA 的结合的影响介导的。这些影响不依赖于激酶活性,而是依赖于 AMPK 的激活构象。AMPK 对 PPAR-α 和 -γ 的抑制可能允许短期过程在细胞投入资源增加脂肪酸氧化能力之前增加能量生成。